Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Advancing the Diagnosis of Hematologic Disorders
- Hematology 2018

Welcome Message

2nd International Conference on Hematology and Oncology is to be held on August 23-25, 2018 at London, UK  will be available to talk about the most recent issues and developments in Future of Hematology and Oncology. Get an association of the best hematology specialists introduced at Hematology 2018 and figure out how it can enhance your systems. This is your opportunity to assess your symptomatic methods and restorative methodologies and talk about with driving hematology specialists and partners how new research and clinical updates can be converted into new patient care procedures. It's with incredible delight and amazing privilege to welcome you to the "2nd International Conference on Hematology and Oncology" booked amid August 23-25, 2018 at London, UK.

It's with awesome delight and significant privilege to welcome you to the "2nd International Conference on Hematology and Oncology" planned amid August 23-25, 2018 at London, UK.

Inside this marvelous setting, we intend to convey a meeting that will surpass your desires. Amid the current year's Conference, we trust that you will grab the chance to revive on-going associations and start new ones with your partners from around the world

The Conference will be sorted out with the theme "Propelling the Diagnosis of Hematologic Disorders"

Hematology 2018 envisions more than 500 members around the world to encounter interesting Keynote addresses, Oral and Poster introductions. This year gathering will offer adequate open doors for all partners taking a shot at Hematological Oncology, Pediatric Hematology and Hematological Malignancies to uncover their exploration work.

Our meeting expects to assemble the Researchers, vital specialists, specialists, hematologists and analysts chipping away at blood from both scholarly world and medicinal services industry, Business Delegates, Scientists and understudies over the globe to give a worldwide discussion to the scattering of unique research comes about, new thoughts and functional advancement encounters.

The current year's Conference program, combined with the Business Opportunity Exchange, is an occasion you can't bear to miss!

Sessions

Session on: Polymerase Chain Reaction in Haematological Malignancies

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

The polymerase chain reaction (PCR) has rapidly become an invaluable technique for the detection, molecular characterization and clinical management of a wide variety of Haematological disorders. PCR provides a rapid method for the generation of large quantities of relatively pure DNA sequences of interest. Two out of every five patients were diagnosed following an emergency admission, and this was associated with advanced disease and poor survival (p < 0.001). Among the 80% of patients treated with curative chemotherapy, survival discrepancies emerged at the point of diagnosis; the adjusted hazard ratio (emergency versus non-emergency) at one month being 4.0 (95% confidence interval 1.9–8.2). No lasting impact was evident in patients who survived for 12 months or more.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Therapeutic Targeting of RNA Splicing in Myelodysplasia

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

RNA splicing factors are exquisitely dependent on the presence of the remaining wild-type (WT) allele to maintain residual normal splicing for cell survival. The high frequency of these mutations in MDS, combined with their mutual exclusivity and noteworthy dependence on the WT allele, make targeting RNA splicing attractive in MDS. To this end, two promising therapeutic approaches targeting RNA splicing are being tested clinically currently. According to Cancer Research UK, the risk varies from five in every 100 cases (5%) to 65 out of every 100 cases (65%), depending on the type of MDS you have.

Related Conferences : ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Management of Hematologic Emergencies

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Hematological crises are characterized as intense dangerous conditions in hematological maladies because of kindhearted blood issue or hematological malignancies or because of its treatment. Nonetheless, the fast improvement of new focused on drugs in growth solution has prompted an expansion in incessantly sick tumor and hematology patients, who are being dealt with forcefully notwithstanding noteworthy comorbidities and higher age. This improvement will prompt an expansion in the quantity of hematologic crises, and these patients will be seen by different masters.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Red Cell Physiology and Disorders

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Incorporates clinical and fundamental investigations of typical or strange RBC layers,   proteins, and catalysts, and hematopoiesis of red platelet antecedents. This classification additionally incorporates clinical and essential investigations of iron deficiency caused by fundamental ailment, red cell underproduction, and red cell overproduction. Incorporates pallor of the elderly, pathophysiology of sickliness of constant ailment and irritation (not identified with annoyed iron digestion), weakness of jungle fever, hemolytic paleness and paroxysmal nighttime hemoglobinuria (aside from PNH related with marrow disappointment, which ought to be submitted to classification 508), and other inborn anemias that don't prompt marrow disappointment. Incorporates physiology, pathophysiology, and administration of all sustenance insufficiencies barring iron.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Quality & Patient Safety in Hematology

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

The medicinal service setting is portrayed by a high level of many-sided quality. Notwithstanding excited endeavors of the social insurance work force, once in a while things turn out badly and deliver accidental damage to the patients. In that capacity, tolerant wellbeing must be considered as one of driving medicinal services challenges. Some preeminent examinations have featured that genuine medicinal blunders may happen rather much of the time, imperiling patient's wellbeing and costing a colossal measure of cash to the human services framework. A restorative blunder is generally characterized as a unintended demonstration, the disappointment of an arranged activity to be finished as planned, the utilization of a wrong intend to accomplish a point when the disappointment cannot be credited to risk. Therapeutic mistakes can be characterized by a few models, for example, the clinical pathway (i.e., indicative, treatment, counteractive action and others), or the subsequent mischief to the patient (i.e., close misses, no damage or hurtful episode).

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Biomarkers in Hematology

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Biomarker is a quantifiable pointer of the earnestness or closeness of some infection state. All the more all things considered a biomarker can be used as a pointer of a physiological state or a particular illness of an animal. Biomarkers in hematology are useful to recognize or investigate blood contaminations in animals.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Climate Changes in the Microenvironment of Chronic Lymphocytic Leukaemia

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Despite ongoing efforts to decipher the cancer genome, discoveries of new targetable genetic lesions within cancer cells are rare. Therefore, alternative approaches are needed. Signals from the microenvironment are increasingly recognized as drivers of disease progression in hematologic and solid cancers. Consequently, there is growing interest in targeting the tumor-microenvironment cross-talk. This review highlights recent therapeutic advances in targeting the microenvironment in chronic lymphocytic leukemia (CLL). The number of new cases of chronic lymphocytic leukemia was 4.7 per 100,000 men and women per year. The number of deaths was 1.3 per 100,000 men and women per year. These rates are age-adjusted and based on 2012-2017 cases and deaths.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Principles of Treatments in Malignant Hemopathies

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

This study represent the latest researches in the field of molecular medicine, in terms of treatments in malignant hemopathies, emerged from the P53 gene deletion in human lymphoma genome. In recent years proved that the best techniques in the investigation of malignant lymphocytes are the Flow Cytometry, Elisa, ICT and Fluorescence in Situ Hybridization (FISH). This method is used as an alternative to chromosomal banding, a conventional application in molecular medicine. According to the study, a total of 660 cases of Hematological Malignancies were registered between January 2012 and December 2016. Overall, 6075 cases of cancers all sites combined were registered during this study period, indicating that Hematological Malignancies account for around 10.9 % (660/6075) of all cancers recorded. Among the 660 registered cases of Hematological Malignancies, 53 % were males and 47 % were females, with a male to female ratio of 1.1. Thus, overall, men are slightly more affected with Hematological Malignancies than women.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Discovery and Translation in Lymphoma

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Nearly half of all blood cancer cases are lymphomas, or cancers of the lymphatic system, of which there are numerous unique disease subtypes. While the disease can take many forms, recent advances have better characterized how lymphoma cells proliferate and interact with other cells and tissues, leading to the development of powerful, targeted therapies with fewer side effects than traditional approaches. New cases of Hodgkin lymphoma in 2017, UK. The 5-year survival rate for all people with Hodgkin lymphoma is 86%. The 5-year survival rates are 85% for men and 87% for women. The 5-year survival rate for stage I and stage II Hodgkin lymphoma is 90%. For stage III, the 5-year survival rate is 80% and for stage IV, it is 65%.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Transcription Factors in Hematopoiesis and Hematologic Disease

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Hematopoiesis involves an elaborate regulatory network of transcription factors that coordinates the expression of multiple downstream genes, and maintains homeostasis within the hematopoietic system through the accurate orchestration of cellular proliferation, differentiation and survival. As a result, defects in the expression levels or the activity of these transcription factors are intimately linked to hematopoietic disorders, including leukemia. According to the study, a total of 660 cases of Hematological Malignancies were registered between January 2012 and December 2016. Overall, 6075 cases of cancers all sites combined were registered during this study period, indicating that Hematological Malignancies account for around 10.9 % (660/6075) of all cancers recorded. Among the 660 registered cases of Hematological Malignancies, 53 % were males and 47 % were females, with a male to female ratio of 1.1. Thus, overall, men are slightly more affected with Hematological Malignancies than women

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Complications of Multiple Myeloma

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Diverse myeloma is a hematological (blood) illness that makes in the plasma cells found in the fragile, flexible tissue at the point of convergence of your bones, called bone marrow. Plasma cells are a kind of white platelet responsible for making antibodies (immunoglobulins) which are fundamental for keeping up the body's safe system. Through a complex, multi-step process, sound plasma cells change into debilitating myeloma cells. There are approximately 5,500 people diagnosed with myeloma every year in the UK. It is the second most common form of blood cancer, but only represents 2% of all cancers

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Precision Medicine in Hematological Disorders

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Enhancing precision medicine efforts in hematology will require that sequencing technologies be adopted in drug discovery efforts, and in the assessment of disease predisposition, and response to therapy. In addition, appropriate infrastructure must be developed to integrate genomic and epigenomic medicine into the clinic. The government has announced a further £250 million in funding for genomics.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Immunologic Treatments of Hematologic Malignancies

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

In the field of immunology, including immune evasion, genetic engineering, and adoptive immunotherapy, have generated novel immune-based strategies and improved the utility of existing options, such as allogeneic hematopoietic stem cell transplantation (HSCT). These new approaches offer vast clinical promise to impact a wide array of diseases, including acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), Hodgkin and non-Hodgkin lymphoma, and myeloma, as well as non-malignant hematologic disorders such as sickle cell anemia and other inherited hematologic or metabolic diseases. According to the study, a total of 660 cases of Hematological Malignancies were registered between January 2012 and December 2016. Overall, 6075 cases of cancers all sites combined were registered during this study period, indicating that Hematological Malignancies account for around 10.9 % (660/6075) of all cancers recorded. Among the 660 registered cases of Hematological Malignancies, 53 % were males and 47 % were females, with a male to female ratio of 1.1. Thus, overall, men are slightly more affected with Hematological Malignancies than women

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Drug Discovery in Hematology

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

In every disease area, Phase II had the lowest transition success rate of the four phases. Phase II success rates ranged from a high of 56.6 for Hematology to a low of 23.7% in Psychiatry. Although it is widely known that drug program attrition is high in Phase II, it is interesting to find that the rate of success can vary by 33% among disease groups. The only Phase II success rate above 50% was seen in Hematology, which largely explains how that indication attained the highest LOA from Phase I.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Paediatric Hematology

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Pediatric Hematology Oncology as a claim to fame was conceivable due to the advancement of the study of Hematology, which created microscopy for portraying platelet morphology and techniques for quantitation of these components. Before pediatric blood maladies could be characterized, it was important to build up the ordinary blood estimations of early stages and adolescence. The special highlights of the blood of the infant were the concentration of a considerable lot of the early investigations. After ordinary esteems were set up, particular blood sickness and hematologic disorders of kids started to be depicted in Europe and the United States. Pediatric Hematology Oncology is an expansive and complex region that incorporates bothers of the few shaped components of the blood and their antecedents in the bone marrow, and also the coagulation-fibrinolytic frameworks in the plasma, the reticuloendothelial framework, and malignancies of the blood and strong tissues and organs. The communications of the blood and nourishment have for quite some time been essential territories of study.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Leukemia Immunotherapy

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

The body's insusceptible framework ensures us against illness and contamination. It incorporates a system of cells and organs that assistance guard the body from "antigens" — remote substances, for example, microbes, infections, growths, hurtful poisons and allergens. At the point when antigens are ingested or come into contact with the skin or mucous films, they invigorate an insusceptible reaction: White cells deliver antibodies that "coat" the antigens, stamping them as focuses for other white cells or inactivating the antigens. The other white cells at that point assault and decimate the antigens.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology

Session on: Hematology Nursing

RelatedHematology Conference | Hematology Congress | Hematology Conferences | Hematology Meetings |Hematology Events

Hematology Nurse is prepared to tend to patients with blood sicknesses and scatters. They may likewise help with blood transfusions, blood tests, research, and chemotherapy. In the event that you go into hematology, hope to have more duty than different medical attendants, prescriptive expert, and the capacity to arrange indicative lab work.

Related Conferences: ASH Meeting on Hematologic Malignancies, September 7-8, 2018 Chicago, Illinois; ASH Meeting on Lymphoma Biology, August 2-5, 2018 Chantilly, Virginia; ASH Summit on Emerging Immunotherapies for Hematologic Diseases, July 12-13, 2018, Washington, DC: World Cancer Conference, June 25-27, 2018, Moscow, Russia; Portuguese  Society Of Hematology Annual Meeting, November 16-18, 2018, Vilamoura, Portugal ; Belgian Haematological Society 33rd Annual General Meeting 2018 February 2-3, 2018, Brussels, Belgium; International Congress on Clinical Trials in Oncology and Hemato-Oncology  2018 (ICTO 2018), February 19-20, 2018, Berlin, Germany ; World Congress on Breast Cancer, July 11-13, 2018, London, UK; French Society of Hematology 2018, March 28-30, 2018, Paris, France.

Related AssociationsEuropean School of Hematology (ESH), American Society of HematologyInternational Society Of HematologyThe American  Society Of  Paediatric Hematology/OncologyBritish Society of Hematology,  Canadian Hematology SocietyInternational Society for Laboratory Hematology.

Market Analysis

Worldwide hematology showcase estimate was esteemed around 4.9 billion dollars in 2015 and is relied upon to achieve roughly 5.6 billion dollars by 2018. Sysmex Corporation (Japan), Beckman Coulter, Inc. (U.S.), and Abbott Laboratories (U.S.) represented an offer of 83% of the worldwide hematology advertise in 2013. In 2015, Sysmex Corporation, Abbott Laboratories, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Mindray Medical International Limited, Siemens Healthcare, HORIBA, Ltd. Nihon Kohden Corporation Sinnowa and Drucker Diagnostics are top 10 enter organizations working in this market.

The Americas instructed the biggest offer of 45% of the worldwide hematology advertise at an expected $2,160 million out of 2015. Europe directed the second biggest offer 26% of hematology showcase at an expected $300 million out of 2015

Major Universities around the Globe

Massachusetts Institute of Technology (MIT)

Harvard Medical School

University of California in San Francisco 

The University of Washington’s School of Medicine 

Johns Hopkins University

Stanford University School of Medicine

University of Cambridge 

Medical Center at Columbia University

Medical School at the University College London 

University of Texas Southwestern Medical Center 

University of California 

Yale School of Medicine 

Karolinska Institute

Medical School at the University of North Carolina 

University of Pittsburgh

University of Oxford

Major Societies around the Globe

·         American Society of Hematology

·         Michigan Society of Hematology and Oncology

·         British Society for Hematology

·         Advanced Practitioner Society for Hematology and Oncology

·         European Hematology Association (EHA)

·         Belgian Hematology Society

·         Pennsylvania Society of Oncology and Hematology

·        Hematology Pharmacy Association



About

2nd International Conference on Hematology and Oncology is organizing an outstanding Scientific Exhibition/Program and anticipates the world's leading hematologists, health professionals involved in the profession and practice of hematology. The event will also reflect interest of specialists in the clinical research on Hematology and Oncology. Hematology 2018 is organizing this conference for people to take part and gain a better understanding of such diseases, to access treatment as well as information, advice and support and to have their health monitored more closely.

This International meeting is an effort to make possible interactions among world leading scientists, research scholars, professionals, young researchers from different parts of the world to exchange their knowledge and conduct symposia, show experiments with new innovative techniques that disseminate information about clinical tradition, best practices, skills and knowledge in the field of hematology. In Hematology 2018, international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Hematology.

Benefits of attending:

  •          Networking Opportunities, Grow Your Professional Network
  •         Build Your Knowledge Base
  •          Expand Your Resources
  •          Meet Experts & Influencers Face to Face
  •          Learning in a New Space
  •          Break Out of Your Comfort Zone
  •          New Tips & Tactics
  •          Greater Focus

Scope and Importance

The scope of the Hematology 2018 conference is to bring together the world’s scientific experts to catalyze and advance scientific knowledge about Hematology and Oncology and to present the most recent research findings, and promote and enhance scientific collaborations around the world. It brings together community leaders, scientists, and policy leaders to promote and enhance programmatic collaborations to more effectively address regional, national and local responses to Elderly Population around the world and overcome barriers that limit access to care and services.

Target Audience

Hematology Associations

Hematology scientists

Business people

Research Laboratories

Research Scholars

Organizing Committee Member
OCM Member
Dr. C. Cameron Yin
Professor, Hematopathology
University of Texas MD Anderson Cancer Center
Houston, USA
OCM Member
Cheng Peng
The University of Queensland
Queensland, Australia
OCM Member
ROBERTO CHIARLE
Harvard University
Boston, USA
Venue
&
Hospitality

Renaissance London Heathrow Hotel

Bath Road, Hounslow, TW6 2AQ United Kingdom



Join The Discussion

Contact Desk

Program Enquiry

Steffi Mathew

hematology@alliedconferences.org

+44 20 3769 1755

Sponsors/Exhibiting/Advertising

Steffi Mathew

hematology@alliedmeetings.com

+44 20 3769 1755

General Queries

Steffi Mathew

hematology@alliedconferences.org

+44 20 3769 1755

Previous Conferences

Media Partners

Allied Academies Global Conference Directory

Mail us at

Program Enquiry
hematology@alliedconferences.org
Sponsors/Exhibiting/Advertising
hematology@alliedmeetings.com
General Queries
hematology@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com

Highlights from last year's Convention

Authorization Policy


Copyright © 2018-2019 Allied Academies, All Rights Reserved.